1,884 results on '"Preston, Mark A."'
Search Results
2. Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer
3. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).
4. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
5. Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review
6. America in the World: A History in Documents since 1898, Revised and Updated
7. Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in patients with muscle-invasive bladder cancer (MIBC) undergoing trimodality therapy (TMT).
8. MP43-20 DEVELOPMENT AND EARLY TESTING OF A PROTOTYPE FOR NANOSENSOR-ENABLED CHEMICAL CYSTOSCOPY
9. MP08-15 SMOKING STATUS IS ASSOCIATED WITH POOR MENTAL HEALTH IN BLADDER CANCER PATIENTS AND SURVIVORS
10. PD50-10 FREE PSA AND RISK OF GLEASON GRADE GROUP ≥2 AND FATAL PROSTATE CANCER IN BLACK MEN: IMPLICATIONS FOR RISK-STRATIFIED SCREENING
11. Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes
12. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy
13. Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer
14. A Provider-Facing Decision Support Tool for Prostate Cancer Screening in Primary Care: A Pilot Study
15. THE RELATIONSHIP BETWEEN SMOKING STATUS AND POOR MENTAL HEALTH IN BLADDER CANCER PATIENTS AND SURVIVORS
16. Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool
17. ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
18. NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT
19. Contemporary Perioperative Outcomes of Open Retroperitoneal Lymph Node Dissection for Testicular Cancer
20. Anticoagulation prophylaxis patterns following retroperitoneal lymph node dissection for testis cancer
21. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
22. Institutional trends and safety profile of same-day discharge for robot-assisted laparoscopic radical prostatectomy: A retrospective analysis
23. Goal-Related Feedback Seeking, Receiving Goal-Related Feedback, and Internal Work Motivation: A Two-Sample Mediation Study Using Human Service Case Managers.
24. Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial
25. Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol
26. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism
27. An inter-laboratory study to investigate the impact of the bioinformatics component on microbiome analysis using mock communities
28. The association of diabetes with risk of prostate cancer defined by clinical and molecular features
29. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
30. Gleason 6 Prostate Cancer: Translating Biology into Population Health
31. Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?
32. Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy
33. Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study
34. Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing
35. Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial.
36. Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer
37. Prostate cancer screening in African American men: a review of the evidence
38. Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer
39. Frequent Undetected Ward-Based Methicillin-Resistant Staphylococcus aureus Transmission Linked to Patient Sharing Between Hospitals
40. Assessment of the Ecological Association between Tobacco Smoking Exposure and Bladder Cancer Incidence over the Past Half-Century in the United States
41. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA
42. Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer
43. Does job control buffer work demands' detrimental impact on public child welfare case managers' affective well-being? Extending the nonlinear demand-linear control model
44. Exploring Patterns of Mitomycin C Use in Community Practice Urology
45. Exploiting differential protein stability of a toxin/antitoxin pair for the selective killing of cervical cancer cells
46. Sex specific associations in genome wide association analysis of renal cell carcinoma
47. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories
48. Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era
49. Approach to the Patient with High-Risk Prostate Cancer
50. Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.